How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
93
NVSEF Quote, Financials, Valuation and Earnings
Last price:
$152.77
Seasonality move
:
1.38%
Day range:
$152.77 - $155.26
52-week range:
$97.30 - $155.26
Dividend yield:
2.59%
P/E ratio:
21.34x
P/S ratio:
5.47x
P/B ratio:
6.35x
Volume:
201.7K
Avg. volume:
105.3K
1-year change:
45.85%
Market cap:
$293.1B
Revenue:
$54.5B
EPS (TTM):
$7.16
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Novartis AG has -45.67% downside to fair value with a price target of -- per share.
NVSEF vs. S&P 500
-
Over the past 5 trading days, Novartis AG has overperformed the S&P 500 by 8.4% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Novartis AG does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Novartis AG has grown year-over-year revenues for 9 quarters straight. In the most recent quarter Novartis AG reported revenues of $13.3B.
Earnings Growth
-
Novartis AG has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Novartis AG reported earnings per share of $1.25.
Enterprise value:
317.4B
EV / Invested capital:
3.87x
Price / LTM sales:
5.47x
EV / EBIT:
19.13x
EV / Revenue:
5.82x
PEG ratio (5yr expected):
0.98x
EV / Free cash flow:
20.04x
Price / Operating cash flow:
18.83x
Enterprise value / EBITDA:
14.62x
Gross Profit (TTM):
$40.8B
Return On Assets:
13.19%
Net Income Margin (TTM):
25.61%
Return On Equity:
32.34%
Return On Invested Capital:
18.45%
Operating Margin:
23.41%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $45.4B | $50.3B | $54.5B | $13.2B | $13.3B | |
| Gross Profit | $32.8B | $37.3B | $40.8B | $9.8B | $9.7B | |
| Operating Income | $11.7B | $15.4B | $16.6B | $3.8B | $3.1B | |
| EBITDA | $20B | $21.5B | $21.7B | $5.4B | $4.7B | |
| Diluted EPS | $7.14 | $5.87 | $7.16 | $1.41 | $1.25 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $45.7B | $36.9B | $30.5B | $29.7B | $30.5B | |
| Total Assets | $135.9B | $121.8B | $103.8B | $106.8B | $110.9B | |
| Current Liabilities | $30.2B | $28.7B | $26.4B | $28.7B | $27.3B | |
| Total Liabilities | $68.1B | $62.3B | $57.1B | $62.6B | $64.4B | |
| Total Equity | $67.8B | $59.4B | $46.7B | $44.1B | $46.5B | |
| Total Debt | $27.4B | $24.3B | $22.5B | $26.5B | $30.6B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $14.6B | $17.5B | $19.9B | $4B | $2.2B | |
| Cash From Investing | $5.5B | -$7.4B | -$5.1B | -$3B | -$2.2B | |
| Cash From Financing | -$14.3B | -$11.6B | -$15.4B | -$2.9B | $1.9B | |
| Free Cash Flow | $11.8B | $13.7B | $15.8B | $2.9B | $1.1B | |
NVSEF
Sector
Market Cap
$293.1B
$23.3M
Price % of 52-Week High
98.4%
48.38%
Dividend Yield
2.59%
0%
Shareholder Yield
6.23%
-1.67%
1-Year Price Total Return
45.85%
-21.73%
Beta (5-Year)
0.488
0.502
Dividend yield:
2.59%
Annualized payout:
$3.96
Payout ratio:
-58.55%
Growth streak:
5 years
Technicals
8-day SMA
Buy
Level
$149.53
200-day SMA
Buy
Level
$124.35
Bollinger Bands (100)
Buy
Level
123.39 - 140.29
Chaikin Money Flow
Sell
Level
-201.4K
20-day SMA
Buy
Level
$144.97
Relative Strength Index (RSI14)
Buy
Level
59.83
ADX Line
Buy
Level
30.92
Williams %R
Sell
Level
-14.4892
50-day SMA
Buy
Level
$136.95
MACD (12, 26)
Buy
Level
37.19
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Sell
Level
-50.7K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.0533)
Buy
CA Score
(Annual)
Level (0.0158)
Buy
Beneish M-Score
(Annual)
Level (-2.3494)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-1.7476)
Buy
Piotroski F Score
(Annual)
Level (8)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Stock Forecast FAQ
In the current month, NVSEF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NVSEF average analyst price target in the past 3 months is --.
-
Where Will Novartis AG Stock Be In 1 Year?
According to analysts, the consensus estimate is that Novartis AG share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Novartis AG?
Analysts are divided on their view about Novartis AG share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Novartis AG is a Sell and believe this share price will rise from its current level to --.
-
What Is Novartis AG's Price Target?
The price target for Novartis AG over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NVSEF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Novartis AG is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of NVSEF?
You can purchase shares of Novartis AG via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Novartis AG shares.
-
What Is The Novartis AG Share Price Today?
Novartis AG was last trading at $152.77 per share. This represents the most recent stock quote for Novartis AG. Yesterday, Novartis AG closed at $152.77 per share.
-
How To Buy Novartis AG Stock Online?
In order to purchase Novartis AG stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get NVSEF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NVSEF
Sector
P/E ratio
21.34x
23.47x
PEG ratio
0.98x
-0.01x
P/B ratio
6.35x
1.75x
Price / LTM sales
5.47x
1.53x
Growth Metrics
NVSEF
Sector
Revenue growth
1.39%
3.62%
Earnings growth
-11.19%
9.09%
Revenue (5-year growth)
2.31%
6.22%
Earnings forecast
--
-$0.19
Profitability
NVSEF
Sector
Profitability FY 2025
$40.8B
$2.6M
Return on invested capital
18.45%
-33.62%
Return on assets
13.19%
-29.68%
Return on equity
32.34%
-38.98%
Earnings Date
Last Earnings Date
Feb
4
Next Earnings Date
Feb
6
Estimated Next Earnings Date
May
8
Balance Sheet
NVSEF
Sector
Total cash
$11.6B
$25M
Short term investments
$1.9B
$23.9M
Total assets
$110.9B
$71.9M
Long term debt
$30.6B
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Sell
45
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
61
SLAB alert for Feb 5
Silicon Laboratories, Inc. [SLAB] is up 0.91% over the past day.
Buy
73
ENPH alert for Feb 5
Enphase Energy, Inc. [ENPH] is down 8.53% over the past day.
Sell
25
MRCY alert for Feb 5
Mercury Systems, Inc. [MRCY] is up 2.61% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
